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Abstract
Background: To evaluate results after seven years using prophylactic intracameral cefazolin for the prevention of
endophthalmitis in cataract surgery.
Methods: A prospective, observational study of all patients submitted to cataract surgery over the period January
1996 to December 2009. All cases of postoperative endophthalmitis over that period were reviewed. The patients
were classified in two groups: Group 1 (11,696 patients) operated on between January 1996 and December 2002,
Group 2 (13,305 patients) between January 2003 and December 2009 (in whom a 1 mg/0.1 bolus of intracameral
cefazolin was instilled).
Results: During the study period, 76 cases of endophthalmitis were observed in Group 1, and seven in Group 2.
The rate of postoperative endophthalmitis reduced from 0.63% to 0.05% with a cefazolin injection. The relative risk
(RR) for endophthalmitis in Group 1 against group 2 was 11.45 [95% CI 5.72-22.84, p < 0.001].
Conclusions: An intracameral bolus injection of cefazolin (1 mg in 0.1 ml solution) at the conclusion of the
cataract surgery significantly reduced the rate of postoperative endophthalmitis.
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Background
Endophthalmitis remains a serious complication after
cataract surgery, although prophylactic measures intro-
duced in recent years have reduced the number of
patients with this complication.
Currently there are two streams of opinion towards
endophthalmitis prophylaxis, the use of fourth-generation
quinolones (gatifloxacin and moxifloxacin) topically [1-4],
or the introduction of intracameral cephalosporins, the lat-
ter being cefuroxime (a second generation cephalosporin),
which is the most widely used and accepted [5-10]. How-
ever, our study group [11], as well as Garat et al [12,13],
prefers the use of cefazolin (a first generation cephalos-
porin). Having previously studied the bacteria that cause
endophthalmitis in our environment most frequently, we
prefer cefazolin because of its higher frequency of gram-
positive bacteria in our medium, and because it best cov-
ers infections by such bacteria. Furthermore, cefazolin
shows no corneal toxicity at doses of 1 mg or 2 mg; its
toxicity was established when doses of 5 mg or more were
injected. We consider the risk of an infection caused by a
cefazolin-resistant bacterium low, based on the bacteria
cultured since 1994 and their antibiogram. We consider
there not to be any risk of coverage of gram-negative bac-
teria by cefazolin, and its incidence in endophthalmitis
was low in our Health Care District.
Our two groups are included in the Barcelona
Endophthalmitis Group (GEB), formed by 38 public and
private Hospitals in Catalonia (Spain), who have been
studying the epidemiological factors of postoperative
endophtalmitis and assessing the prophylaxis and treat-
ment of endophtalmitis in our country since 2000.
Appendix 1 gives a list of GEB participating hospitals
and ophthalmologists.
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years of using intracameral cefazolin after cataract sur-
gery at doses of 1 mg in 0.1 ml.
Methods
Since 1996, there has been an ongoing registration of all
postoperative endophthalmitis patients at Hospital St
Joan (Table 1). All cases of postoperative endophthalmi-
tis were studied in the epidemiological unit of the hospi-
tal in order to determine their origin.
Design
A prospective observational study. The population com-
prised all patients submitted to un-combined cataract
surgery in the period from January 1996 to December
2009. All cases of postoperative endophthalmitis were
related. Only patients with phacoemulsification were
included in the study in order to reduce any possible
bias introduced by the technical cataract surgery. Tech-
nical surgery includes a sutureless, clear corneal incision
of 3.2 mm using a venturi (Millenium, Bausch Lomb
®)
phaco unit.
For all patients included in our hospital, the prophy-
lactic measures for reducing the bacterial flora of the
conjunctiva since 1996 were:
￿ Topical 10% povidone-iodine in the skin of peri-
orbital region
￿ Topical 5% povidone-iodine on the conjunctiva
and eyelashes for a minimum of 1 minute
￿ Draping of the peri-orbital region and eyelashes
￿ Postoperative use of eye drops with tobramycin
3.00 mg/mL associated to dexametasone 1.00 mg/
mL instilled every 4 hours (these eye drops were gra-
dually tapered after 1 week), and diclofenac every 6
hours. These drops were continued at week 3, and
the topical diclofenac was used for 1 month after
surgery.
The patients were classified in two groups:
￿ Group 1 included patients operated on from Janu-
ary 1996 to December 2002 (11696 patients), during
which time intracameral cefazolin was not used.
￿ Group 2 included patients operated on from Janu-
ary 2003 to December 2009 (13305 patients) when
we used 1.00 mg/0.1 mL intracamerular cefazolin
was used at the end of cataract surgery.
Antibiotic selection
The choice of cefazolin as an intracameral antibiotic was
based on bacterial and antibiogram studies in
endophthalmitis cases since 1996 (Table 2), and the
antibiogram (Table 3).
Table 3 was created from the analysis of an antibio-
gram of 14,626 cultures obtained from samples of
patients with community- and hospital- acquired infec-
tions (urinary infections, pneumonia, sepsis, etc.), which
occurred during 2002 in the population serviced by our
Health Care District. In the table we presented only the
results obtained with the bacteria cultured in
endophthalmitis observed in our area, and compared
with the prophylactic antibiotics most frequently used
for endophthalmitis in Spain (cefazolin, cefuroxime, van-
comicyn, and levofloxacin). At this point we should
point out that in our Hospital in cases of allergy to
cephalosporines we used vancomicyn.
The dose of cefazolin (1 mg/0.1 ml) was based on our
calculations that this anterior chamber concentration of
cefazolin exceeded the minimum inhibitory concentra-
tion (MIC) for susceptible bacteria.
Inclusion criteria
Patients in our dependent Health care district who were
submitted to cataract surgery by phacoemulsification by
clear cornea incision.
Table 1 Description of cases of endophthalmitis since 1996
Group 1
1996-2002
1996 1997 1998 1999 2000 2001 2002 Total
Cases* 8991 1 1 2 1 3 1 4 7 6
Percentage 0.637% 0.613% 0.629% 0.664% 0.634% 0.687% 0.692% 0.649%
Number of operations** 1256 1467 1430 1656 1892 1972 2023 11696
Group 2 2003-2009
Cases* 11102117
Percentage 0.058% 0.052% 0.055% 0.000% 0.101% 0.050% 0.049% 0.052%
Number of operations** 1707 1911 1812 1874 1967 1997 2037 13305
Cases* = number of cases of endophthalmitis (proven + unproven) occurring each year
Patients** = Number of cataract interventions carried out each year
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Patients admitted for extracapsular cataract surgery.
Patients allergic to cephalosporins and to whom we gave
intracamerular vancomicyn.
Ethics
Local ethics committee approval the study CEIC HUSJ-
2002-DEC-1022
Definition of acute postoperative endophthalmitis
Following the criteria [14] in the Endophthalmitis
Vitrectomy Study (EVS), the ophthalmologist diagnosed
presumed acute endophthalmitis. If a positive culture of
a vitreous sample was obtained, we defined the case as a
proven acute endophthalmitis. In all proven and unpro-
ven cases, the patients had swollen lids, pain and an
opaque vitreous.
Microbiological method
Vitreous samples obtained by the ophthalmologist were
immediately processed, then a Gram stain was carried
out and the sample cultivated in petri dishes. Antibio-
gram susceptibility was measured according to the cri-
teria laid down by the Spanish Committee for the
Standardization of the Sensitivity and Resistance to
Antimicrobials (MENSURA) [15-17] which includes
members of the Spanish Society of Chemotherapy and
the Spanish Society for Infectious Diseases and Micro-
biology [15]. This is a body with responsibilities similar
to those of the National Committee for Clinical Labora-
tory Standards [18].
Statistical analyses for descriptive statistics were per-
formed using SPSS statistical software (version 17.0).
The data obtained was analysed with frequency and
descriptive statistics. Values are expressed as mean ±
SEM, and statistical significance was determined using
the Student’s t-test for paired data.
Results
Demographic results in the two groups of patients
Group 1. Formed by patients without intracameral
instillation of cefazolin. This group included a total of
11,696 patients, with a median age of 69.8 ± 7.55 years
(53-89 years); a total of 6785 (58.01%) were females.
Group 2. Formed by patients with intracameral instilla-
tion of cefazolin at doses of 1 mg/0.1 mL. This group
included a total of 13,305 patients, with a median age of
66.17 ± 7.83 years (53-81 years); a total of 7717
(58.00%) were females. The difference between groups
was not statistically significant in the Student’s t-test.
Endophthalmitis cases
In Group 1 there were 76 postoperative endophthalmitis
cases, at a median elapsed time of 5.37 ± 2.33 days after
Table 2 Bacteria cultured in cases of endophthalmitis in
the two groups.
Number of
cases
(percentage)
1996-2002
Number of
cases
(percentage)
2003-2009
Negative cultures 26 (34.21%) 2 (28.57%)
Gram positive (96.00%)
Staphylococcus epidermidis 37 (74.00%)
Staphylococcus aureus methicillin
sensible
5 (10.00%)
Streptococcus pneumoniae 2 (4.00%)
Streptococcus
viridans
1 (2.00%)
Bacillus spp 3 (6.00%)
Corynebacterium 1 (14.28%)
Gram negative (4.00%)
E Colli 1 (2.00%)
Serratia marcensens 1 (2.00%)
Klebsiella pneumoniae 1 (14.28%)
Pseudomona aeroginosa 1 (14.28%)
Proteus mirabilis 2 (28.57%)
Table 3 Sensitivity to antibiotics of the most frequent
bacteria in our Area in 2002
Germen Cefazolin Cefuroxime Levofloxacin Vancomicyn
Gram positive
Staphilococcus
Aureus
100%
(≤2 ≥4)*
96%
(≤2 ≥4)
65%
(≤0.5 ≥8)
66%
(≤4 ≥32)
Staphilococcus
Aureus
MARSA
54%
(≤2 ≥4)
48%
(≤2 ≥4)
17.64%
(≤0.5 ≥8)
99,02%
(≤4 ≥32)
Staphilococcus
Epidermidis
100%
(≤2 ≥4)
97%
(≤2 ≥4)
27%
(≤0.5 ≥8)
97%
(≤4 ≥32)
Streptococcus
Pneumoniae
96%
(≤2 ≥8)
79.15%
(≤0.12 ≥2)
89%
(≤2 ≥8)
100%
(≤1 -
f * )
Gram negative
E. Colli 85%
(≤4 ≥32)
87%
(≤4 ≥32)
71%
(≤0.5 ≥8)
90%
(≤4 ≥32)
Pseudomona
Aeroginosa
18%
(≤4 ≥32)
15%
(≤4 ≥32)
65%
(≤2 ≥8)
65%
(≤4 ≥32)
Proteus
Mirabilis
79%
(≤4 ≥32)
82%
(≤4 ≥32)
70%
(≤0.5 ≥8)
100%
(≤4 ≥32)
Klebsiella
Pneumoniae
75%
(≤4 ≥32)
79%
(≤4 ≥32)
100%
(≤0.5 ≥8)
95%
(≤4 ≥32)
(≤2 ≥4)* = MIC (minimum inhibitory concentration) = Critical concentrations
in μg/ml (critical concentration of susceptibility, critical concentration of
resistance), according to the recommendations of MENSURA to the
interpretation of antibiogram.
-
f * = Unknown, we do not know the mechanisms of resistance, or the
measure for resistance.
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the following sub-classified gram-positive cultured bac-
teria: 9 cases (39.13%) of Staphylococcus epidermidis,4
cases (17.39%) of staphylococcus aureus and 2 cultures
(8.70%) positive for Streptococcus spp. The gram-nega-
tive bacteria gave a culture positive for Klebsiella pneu-
moniae (4.35%). Group 2, there were seven
postoperative endophthalmitis cases, oat a median
elapsed time of 5.41 ± 2.29 days after surgery. The sta-
tistical study of differences in respect to first group were
significant at p < 0.001, RR: 11.45 [95% CI 5.72-22.84].
The bacteria cultured were:
￿ The first case involved patients with diabetes melli-
tus type II, treated with insulin for 30 years, with macro
vascular disease with symptoms of intermittent claudica-
tion. The culture was positive for a Gram-negative bac-
terium (Klebsiella pneumoniae).
￿ The second case was a patient who lived alone and
who had serious social problems; the patient also had
domestic animals at home. The culture was positive for
a Gram-positive anaerobic bacterium (Corynebacterium).
￿ The third case, positive for Proteus mirabilis,
occurred in a 68-year-old woman with type II diabetes
mellitus of long evolution (22 years), with poor glycae-
mic control and peripheral vascular macroangiopathy.
￿ The fourth case, positive for Proteus mirabilis,
occurred in a 77-year-old man with type II diabetes
mellitus and poor glycaemic control.
￿ The fifth case, positive for Pseudomona aeroginosa,
occurred in a 73-year-old man with viral C-hepatitis.
￿ Negative cultures: two cases of negative cultures
(28.57%) were observed in this period of time.
In the groups of patients that received intracamerular
cefazolin, there were no cases observed of toxic effect at
the corneal or retina levels, nor was there any hypersen-
sitivity reaction.
Statistical analysis
The relative risk for presenting with endophthalmitis in
Group 1 compared with Group 2 was 11.45 [95% CI
5.72-22.84, p < 0.001]. When limiting the analysis to
proven cases (50 cases in Group 1, against 5 cases in
Group 2), the estimators of the relative risk were 14.07
[95% CI 7.68 - 24.48, p < 0.001].
Visual acuity
1. In Group 1 (period 1996-2002) 38 over 76
patients (50%) had a final visual acuity (VA) over 0.1
a n ds i xp a t i e n t s( 7 . 9 % )h a dV A>0 . 4o nt h eS n e l l e n
charts. There were ten patients with no light percep-
tion (four cases with negative culture, one case pro-
duced by Seratia marcensens,a n df i v ec a s e so f
Streptococcus pneumoniae). Staphilococcus epidermi-
dis in 18 cases caused a final VA between 0.1 and
0.4, and in 14 cases a final VA between light percep-
tion and 0.1; the Staphilococcus aureus predomi-
nantly produced a final VA between light perception
and 0.1 (four cases) and only one case with final VA
> 0.4 on the Snellen charts (Table 4).
2. In Group 2 (period 2003-2009) four patients had
final VA of no light perception (two cases with
gram-negative bacteria, one case with negative cul-
ture and one case produced by gram-positive cory-
nebacterium). In the other three cases, the final VA
was inferior to 0.1 on the Snellen charts (two cases
with gram-negative bacteria and one with a negative
culture) (Table 4).
Discussion
In our health care district we had a high level of
endophthalmitis. Previously, the intracamerular use of
antibiotics, as we point out in the present study in
group 1, lead to the incidence of endophthalmitis at a
rate of 0.649%. This value is higher than that reported
in other countries [2,6,8,14], but the incidence in Spain
was also higher than other study groups, Garcia-Saenz
et al [19] found an incidence of 0.59% (95% CI, 0.50%-
0.70%) between January 1999 and September 2005, and
Garat et al showed an incidence of 0.422% (95% CI
0.279-0.613) in their studies [12,13]. Because our centre
had an excessive number of endophthalmitis cases
despite using all means of regular prophylaxis (a sterile
ophthalmology operating room, povidone-iodine in skin
(at 10%) and conjunctival sac (at 5%) with few surgical
intraoperative complications etc.), we decided to use
intracamerular antibiotics after cataract surgery.
Peyman et al. published the first report of successful
prophylactic bolus injections of antibiotics into the ante-
rior chamber in 1977 [20]. Despite the efficacy of the
injections, the technique later becomes forgotten about.
It is well-established that the source of most infecting
agents is the patients’ ocular flora; the most frequently
reported being bacteria gram-positive, coagulase-nega-
tive, or positive staphylococcus.
Swedish physicians have pioneered the use of intra-
cameral cefuroxime since 2002, with excellent outcomes
in 400,000 surgical interventions. Montan et al. pub-
lished the efficacy of cefuroxime 1 mg intracameral
[5,6], a practice that has lowered the rate of postopera-
tive endophthalmitis from 0.26% to 0.06%. The large,
prospective, multi-centred study, the European Society
of Cataract Refractive Surgeons (ESCRS) confirmed the
Swedish experience, finding that an injection of cefurox-
ime at the end of the surgery reduced endophthalmitis
rates to just 0.05% [8-10].
We chose to use cefazolin, which is recommended by
the Department of Microbiology and the Infectious
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oxime because it is a first generation cephalosporin and
has a wide range of activity against gram-positive bac-
teria in our Health Care District, rather than a second-
generation cephalosporin, such as cefuroxime. A study
in our Health Care District by Vila-Corcoles et al [21],
showed an increased resistance of Streptococcus pneu-
moniae to cefuroxime but not to cefazolin.
It is interesting to observe in Table 3 that cefazolin
and cefuroxime present a similar antibiotic resistance
pattern, with regard to both gram-positive and gram-
negative bacteria. Therefore, we still believe that cefazo-
lin is a good option as a prophylaxis for endophthalmi-
tis, and its substitution for cefuroxime is not important
for reducing the number of cases of endophthalmitis.
However, by using cefazolin, there is still a risk of infec-
tion by gram-negative bacteria, which is why the major-
ity of proven cases of endophthalmitis in Group 2 (4/5
cases were gram-negative) were caused by this type of
bacteria. This is clearly a limitation in the use of cefazo-
lin as a prophylaxis for endophthalmitis.
The lack of availability of eye-drops of fourth-genera-
tion quinolones in Spain is the most obvious reason for
the preference for intracamerular antibiotics in the pro-
phylaxis of endophthalmitis. Since June 2010, a moxi-
floxacin eye-drop has been available in Spain, with more
possibilities of prophylaxis.
Results show that final VA was worse in Group 2 than
in group 1. The explanation for this can be found in the
type of bacteria that cause endophthalmitis. We found
Corynebacterium, Klebsiella pneumonia, Pseudomona
aeroginosa,a n dProteus mirabilis in group 2. All these
bacteria were poorly sensitive to cefazolin. Negative cul-
ture was observed in a 34.21% of cases in group 1 and
28.57% in Group 2, similar to other studies, such as the
Endophthalmitis Vitrectomy Study (EVS), with values
near to 30%.
Conclusions
Intracameral bolus injection of cefazolin in cataract sur-
gery demonstrated prophylactic efficacy in diminishing
the rate of postoperative endophthalmitis in our hospi-
tal, at two doses of 1 mg in 0.1 ml solution.
Furthermore, a close relationship between with the
Department of Microbiology, and the Infectious Dis-
eases Committee of our Hospital is essential for devel-
oping a proper antibiotic prophylaxis.
Further studies are needed with a larger number of
patients in order to fully determine the effectiveness of
cefazolin and its non-toxicity at corneal endothelium
level.
Appendix 1
Hospitals that form the Barcelona Endophtalmitis Group
(GEB). http://gebcn.org/geb.html
01. Hospital Sant Pau: Dr. Jesus Diaz
02. Hospital Clínic: Dra. Socorro Alforja - Dr. Joan
Giralt
03. Hospital Bellvitge: Dr. Marc Rubio
04. Hospital Vall d’Hebron: Dr. Alex Fonollosa
05. Hospital General d’Hospitalet: Dra. Magela Garat
06. Hospital Germans Trias i Pujol (Can Ruti): Dr.
Anglada
07. Hospital Parc Taulí: Dr. D. Muntaner - Dra. MªT.
Sellarés - Dra. C. Guardia
08. Mutua de Terrassa: Dra. Silvia Freixes
09. IMAS (H. Esperança i Mar): Dr. Daniel Vilaplana -
Dr. Poposki
10. Hospital St. Rafael: Dra. Ciprés
11. Hospital Viladecans: Dr. Sergi Sedó
Table 4 Final visual acuity in patients with endophthalmitis.
Group 1
(1996-2002)
Culture No light perception Light perception
to < 0.1
0.1 to 0.4 > 0.4
Gram positive 5 (Strp. Pneumoniae, Bacillus spp.) 18* 19** 6***
Gram negative 1 (Serratia marcensens)1 ( E. Colli)
Negative culture 4 10 12
Group 2
(2003-2009)
Culture No light perception Light perception to < 0.1 0.1 to 0.4 > 0.4
Gram positive 1 (Corynebacterium)
Gram negative 2(Klebsiella pneumoniae, Pseudomona aeroginosa)2 ( Proteus mirabilis)
Negative culture 1 1
18* = 14 cases of Staph. Epidermidis and 4 cases of Staph. Aureus
24** = 18 cases of Staph. Epidermidis and 1 case of Staph. Aureus
6*** = One case of Strp. Viridans, and four cases of Staph. Epidermidis
NA = No patients with negative culture endophthalmitis in Group 1, and no patients in Group 2 with Gram-positive bacteria endophthalmitis.
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Page 5 of 712. Institut Català de la Retina: Dra. Sust
13. Institut Oftalmic de Barcelona: Dra. Laura Sararols
14. Instituto de Microcirugia Ocular: Dra. Isabel Nieto
- Dra. Elena Arrondo
15. Hospital General de Catalunya: Dr. Rouras
16. Clínica Barraquer: Dr. Remberto Escoto
17. Hospital Espirit Sant: Dr. Rouras - Dr. Amias
18. Hospital Granollers: Dr. Jarek Hernecki
19. Hospital de Terrassa: Dr. Jose Juan Escobar - Dr.
Jose Pradas
20. Institut Condal d’Oftalmologia (ICO): Dra. Sararols
21. Hospital Municipal de Badalona: Dra. Estela
Barnola
22. OFTALMO: Dr. J. Cabot
23. Clínica de Vic i Hospital General de Vic: Dr. Man-
uel Amén
24. Consulta GMOftalmo: Dr. Gallofré
2 5 .H o s p i t a ld eN e n sd eB a r c e l o n a :D r .J .F l o r s
Despranell
26. Clinica Quiron: Dr. Aureli Rilo
27. Institut Oftalmológic Tres Torres: Dr. Emili Juarez
28. Hospital de Mollet: Dr. Francisco Goñi
29. Hosp. Universitari Josep Trueta: Dra. Flor Escalada
30. Hosp. Universitari Sant Joan de Reus: Dr. Pere
Romero Dra. Isabel Mendez
31. Hosp. Universitari Joan XXIII Tarragona: Drs.
Perez i Pardo
32. Hosp Verge de la Cinta de Tortosa: Dr. J Colome
33. Hosp Son Dureta, Palma de Mallorca: Dr. José
Luis Olea
34. Clinica Sagrada Familia i Corachan: Dr. Carlos
Martin
35. Clínica Plató: Dr. Joan Pujol - Dr. Sergi Miserachs
36. Institut Oftalmológic de Menorca: Dr. Pere
Vilallonga
37. Hospital Sant Joan de Deu de Martorell: Dra. Mª
Carmen del Aguila
38. CEM (Centro Especializado Microcirugía): Dra.
Laura Sararols
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